Literature DB >> 18851679

The level of APOBEC3G (hA3G)-related G-to-A mutations does not correlate with viral load in HIV type 1-infected individuals.

Nzovu K Ulenga1, Abdoulaye Dieng Sarr, Donald Hamel, Jean-Louis Sankale, Souleymane Mboup, Phyllis J Kanki.   

Abstract

The APOBEC family of mammalian cytidine deaminases, such as APOBEC3G (hA3G), has been demonstrated to function as a host viral restriction factor against HIV-1. hA3G has been shown to cause extensive G-to-A mutations in the HIV-1 genome, which may play a role in viral restriction. To investigate the role of G-to-A mutations in HIV-1 pathogenesis, we isolated, amplified, and sequenced HIV-1 sequences (vif, gag, and env) from 29 therapy-naive HIV-1-infected individuals. The levels of G-to-A mutations correlated with the expression levels of hA3G in the vif (rho = 0.438, p = 0.041) and the env regions (rho = 0.392, p = 0.038), but not in the gag region (rho = 0.131, p = 0.582). There is no correlation between viral load and the level of G-to-A mutations in the vif (rho = 0.144, p = 0.522), env (rho = 0.168, p = 0.391), or gag regions (rho = -0.254, p = 0.279). Taken together, these findings suggest that the hA3G-induced G-to-A mutations may not be the mechanism by which hA3G restricts or controls viral replication. Thus, hA3G might be restricting viral growth in infected individuals through a mechanism that is independent of the cytidine deaminase activities of hA3G.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18851679      PMCID: PMC2928122          DOI: 10.1089/aid.2008.0072

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  31 in total

1.  Comment on "Inhibition of hepatitis B virus replication by APOBEC3G".

Authors:  Christine Rösler; Josef Köck; Michael H Malim; Hubert E Blum; Fritz von Weizsäcker
Journal:  Science       Date:  2004-09-03       Impact factor: 47.728

2.  Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.

Authors:  Edmund N C Newman; Rebecca K Holmes; Heather M Craig; Kevin C Klein; Jaisri R Lingappa; Michael H Malim; Ann M Sheehy
Journal:  Curr Biol       Date:  2005-01-26       Impact factor: 10.834

Review 3.  Retroviral restriction by APOBEC proteins.

Authors:  Reuben S Harris; Mark T Liddament
Journal:  Nat Rev Immunol       Date:  2004-11       Impact factor: 53.106

4.  The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools.

Authors:  J D Thompson; T J Gibson; F Plewniak; F Jeanmougin; D G Higgins
Journal:  Nucleic Acids Res       Date:  1997-12-15       Impact factor: 16.971

5.  Interactive analysis of phylogeny and character evolution using the computer program MacClade.

Authors:  W P Maddison; D R Maddison
Journal:  Folia Primatol (Basel)       Date:  1989       Impact factor: 1.246

6.  Relation between HIV-2 proviral load and CD4+ lymphocyte count differs in monotypic and dual HIV infections.

Authors:  A D Sarr; S Popper; I Thior; D J Hamel; J L Sankalé; T Siby; R Marlink; M Essex; S Mboup; P Kanki
Journal:  J Hum Virol       Date:  1999 Jan-Feb

7.  Deoxyribonucleoside triphosphate pool imbalances in vivo are associated with an increased retroviral mutation rate.

Authors:  J G Julias; V K Pathak
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

8.  Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells.

Authors:  Ya-Lin Chiu; Vanessa B Soros; Jason F Kreisberg; Kim Stopak; Wes Yonemoto; Warner C Greene
Journal:  Nature       Date:  2005-04-13       Impact factor: 49.962

9.  Prevalence and risk determinants of human immunodeficiency virus type 2 (HIV-2) and human immunodeficiency virus type 1 (HIV-1) in west African female prostitutes.

Authors:  P Kanki; S M'Boup; R Marlink; K Travers; C C Hsieh; A Gueye; C Boye; J L Sankalé; C Donnelly; W Leisenring
Journal:  Am J Epidemiol       Date:  1992-10-01       Impact factor: 4.897

10.  Cytidine deamination of retroviral DNA by diverse APOBEC proteins.

Authors:  Kate N Bishop; Rebecca K Holmes; Ann M Sheehy; Nicholas O Davidson; Soo-Jin Cho; Michael H Malim
Journal:  Curr Biol       Date:  2004-08-10       Impact factor: 10.834

View more
  23 in total

1.  In vivo HIV-1 hypermutation and viral loads among antiretroviral-naive Brazilian patients.

Authors:  Mariana Leão de Lima-Stein; Wagner Tadeu Alkmim; Maria Clara de Souza Bizinoto; Luis Fernandez Lopez; Marcelo Nascimento Burattini; Juliana Terzi Maricato; Leila Giron; Maria Cecília Araripe Sucupira; Ricardo Sobhie Diaz; Luiz Mario Janini
Journal:  AIDS Res Hum Retroviruses       Date:  2014-08-25       Impact factor: 2.205

2.  Long-Range HIV Genotyping Using Viral RNA and Proviral DNA for Analysis of HIV Drug Resistance and HIV Clustering.

Authors:  Vlad Novitsky; Melissa Zahralban-Steele; Mary Fran McLane; Sikhulile Moyo; Erik van Widenfelt; Simani Gaseitsiwe; Joseph Makhema; M Essex
Journal:  J Clin Microbiol       Date:  2015-06-03       Impact factor: 5.948

3.  Quantification of deaminase activity-dependent and -independent restriction of HIV-1 replication mediated by APOBEC3F and APOBEC3G through experimental-mathematical investigation.

Authors:  Tomoko Kobayashi; Yoshiki Koizumi; Junko S Takeuchi; Naoko Misawa; Yuichi Kimura; Satoru Morita; Kazuyuki Aihara; Yoshio Koyanagi; Shingo Iwami; Kei Sato
Journal:  J Virol       Date:  2014-03-12       Impact factor: 5.103

Review 4.  Identifying and characterizing recently transmitted viruses.

Authors:  Brandon F Keele
Journal:  Curr Opin HIV AIDS       Date:  2010-07       Impact factor: 4.283

5.  Remarkable lethal G-to-A mutations in vif-proficient HIV-1 provirus by individual APOBEC3 proteins in humanized mice.

Authors:  Kei Sato; Taisuke Izumi; Naoko Misawa; Tomoko Kobayashi; Yoshiki Yamashita; Masahide Ohmichi; Mamoru Ito; Akifumi Takaori-Kondo; Yoshio Koyanagi
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

6.  Differential Activity of APOBEC3F, APOBEC3G, and APOBEC3H in the Restriction of HIV-2.

Authors:  Morgan E Meissner; Nora A Willkomm; Jamie Lucas; William G Arndt; Sarah F Aitken; Emily J Julik; Sunanda Baliga; Louis M Mansky
Journal:  J Mol Biol       Date:  2021-11-10       Impact factor: 5.469

7.  Analysis of the percentage of human immunodeficiency virus type 1 sequences that are hypermutated and markers of disease progression in a longitudinal cohort, including one individual with a partially defective Vif.

Authors:  Anne Piantadosi; Daryl Humes; Bhavna Chohan; R Scott McClelland; Julie Overbaugh
Journal:  J Virol       Date:  2009-06-03       Impact factor: 5.103

Review 8.  Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics.

Authors:  John S Albin; Reuben S Harris
Journal:  Expert Rev Mol Med       Date:  2010-01-22       Impact factor: 5.600

Review 9.  Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors.

Authors:  Simon Henriet; Gaëlle Mercenne; Serena Bernacchi; Jean-Christophe Paillart; Roland Marquet
Journal:  Microbiol Mol Biol Rev       Date:  2009-06       Impact factor: 11.056

10.  APOBEC3G expression and hypermutation are inversely associated with human immunodeficiency virus type 1 (HIV-1) burden in vivo.

Authors:  Yordanka Kourteva; MariaPia De Pasquale; Tara Allos; Chara McMunn; Richard T D'Aquila
Journal:  Virology       Date:  2012-05-12       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.